AN INTEGRATED BIOINFORMATICS AND COMPUTATIONAL DRUG DESIGN FRAMEWORK FOR TARGET IDENTIFICATION, LEAD DISCOVERY, AND LEAD OPTIMIZATION IN MODERN DRUG DEVELOPMENT

Abstract

The modern drug discovery paradigm has undergone a transformative shift with the integration of bioinformatics and computational drug design approaches. This comprehensive review examines the synergistic application of computational methodologies across the entire drug development pipeline, from target identification through lead optimization. We analyze recent advances in bioinformatics-driven target identification, including network-based approaches, machine learning algorithms, and multi-omics integration strategies. Virtual screening methodologies for lead discovery are evaluated, encompassing both structure-based and ligand-based approaches, with emphasis on emerging deep learning techniques. Lead optimization strategies utilizing free energy calculations, molecular dynamics simulations, and AI-driven generative models are critically assessed. Furthermore, we explore integrated frameworks that unify these computational approaches into cohesive pipelines, highlighting successful case studies across therapeutic areas including oncology, infectious diseases, and neurodegenerative disorders. Current challenges including data quality, model interpretability, and experimental validation are discussed alongside future directions emphasizing explainable AI, quantum computing applications, and personalized medicine approaches. This review demonstrates that the strategic integration of bioinformatics and computational drug design represents a powerful paradigm for accelerating drug discovery while reducing costs and improving success rates.